ten percent Uses in NOTICE OF UNSUITABILITY OR COMPLAINTS LIFENET HEALTH Clause

NOTICE OF UNSUITABILITY OR COMPLAINTS LIFENET HEALTH from Processing Agreement

This Amended and Restated AXOGEN Nerve Tissue Processing Agreement (Agreement) consists of this signature page, the attached Terms and Conditions, and the Exhibits marked below. This Agreement authorizes LIFENET HEALTH to process human cadaveric tissue for AXOGEN. The term of this Agreement shall commence on the Effective Date and shall end as provided in the Terms and Conditions. For purposes of this Agreement, the Effective Date shall be the last date executed below. This Agreement becomes legally binding upon signature below by authorized representatives of the parties, and supersedes the AXOGEN Nerve Tissue Processing Agreement by and between the parties, dated November 16, 2007 (the Original Agreement).

NOTICE OF UNSUITABILITY OR COMPLAINTS LIFENET HEALTH. shall notify AXOGEN of problems with any nerve tissue provided for Processing, and consult with and follow instructions from AXOGEN as to the disposition of such nerve tissue. AXOGEN and LIFENET HEALTH will immediately notify the other regarding any adverse events or complaints regarding Product. AXOGEN shall have the right to reject any Product supplied that does not meet the Product Specifications (Nonconforming Product) by delivering written notice of such Nonconforming Product within a reasonable time frame agreed by the parties. If such Nonconforming Product is (a) caused by the negligence or misconduct of LIFENET HEALTH or (b) failure of LIFENET HEALTH to follow AXOGENs Processing standards or applicable laws, LIFENET HEALTH shall reduce proportionally the fee per batch; for example, if ten percent (10%) of the batch was determined to be Nonconforming Product, if as a result of either 5(a) or 5(b), the fee per batch would be reduced by ten percent (10%). A batch is equal to one donor.

NOTICE OF UNSUITABILITY OR COMPLAINTS LIFENET HEALTH from Amended and Restated

This Amended and Restated AXOGEN Nerve Tissue Processing Agreement (Agreement) consists of this signature page, the attached Terms and Conditions, and the Exhibits marked below. This Agreement authorizes LIFENET HEALTH to process human cadaveric tissue for AXOGEN. The term of this Agreement shall commence on the Effective Date and shall end as provided in the Terms and Conditions. For purposes of this Agreement, the Effective Date shall be the last date executed below. This Agreement becomes legally binding upon signature below by authorized representatives of the parties, and supersedes the AXOGEN Nerve Tissue Processing Agreement by and between the parties, dated November 16, 2007 (the Original Agreement).

NOTICE OF UNSUITABILITY OR COMPLAINTS LIFENET HEALTH. shall notify AXOGEN of problems with any nerve tissue provided for Processing, and consult with and follow instructions from AXOGEN as to the disposition of such nerve tissue. AXOGEN and LIFENET HEALTH will immediately notify the other regarding any adverse events or complaints regarding Product. AXOGEN shall have the right to reject any Product supplied that does not meet the Product Specifications (Nonconforming Product) by delivering written notice of such Nonconforming Product within a reasonable time frame agreed by the parties. If such Nonconforming Product is (a) caused by the negligence or misconduct of LIFENET HEALTH or (b) failure of LIFENET HEALTH to follow AXOGENs Processing standards or applicable laws, LIFENET HEALTH shall reduce proportionally the fee per batch; for example, if ten percent (10%) of the batch was determined to be Nonconforming Product, if as a result of either 5(a) or 5(b), the fee per batch would be reduced by ten percent (10%). A batch is equal to one donor.